Di Yi Cai Jing
Search documents
3连板南京熊猫:尚无与脑机接口相关的成熟产品,亦未形成相关销售收入
Di Yi Cai Jing· 2026-01-07 09:47
(本文来自第一财经) 南京熊猫发布异动公告称,公司关注到近期脑机接口概念引发市场广泛关注,现作如下说明:公司主营 业务聚焦智慧交通与平安城市、工业互联网与智能制造、绿色服务型电子制造三大领域,目前未发生任 何变化。截至目前,公司尚无与脑机接口相关的成熟产品,亦未形成相关销售收入,相关概念不会对公 司当前生产经营活动产生实质性影响。 ...
高能环境:2025年净利同比预增55.66%-86.79%
Di Yi Cai Jing· 2026-01-07 09:46
高能环境发布2025年度业绩预告,预计归属于上市公司股东的净利润为7.50亿元至9.00亿元,同比增长 55.66%到86.79%。 ...
泰胜风能:与多家整箭制造商开展战略合作
Di Yi Cai Jing· 2026-01-07 09:42
(文章来源:第一财经) 泰胜风能在互动平台表示,公司积极推动商业航天业务的开拓,与多家整箭制造商开展基于技术研发的 战略合作。 ...
创新药出海热潮下,这家药企为何收回对外授权
Di Yi Cai Jing· 2026-01-07 09:37
Core Viewpoint - The company Yiming Anke has decided to terminate its licensing agreement with Axion for two drug candidates, IMM2510 and IMM27M, and will reclaim all rights previously granted to Axion, including global development and commercialization rights outside Greater China [1] Group 1: Licensing Agreement Details - The initial licensing agreement with Axion began in August 2024, with a collaboration amount exceeding $2 billion [1] - Yiming Anke has received a total of $35 million in upfront and milestone payments from Axion prior to the termination of the agreement [1] Group 2: Reasons for Termination - The CEO of Yiming Anke stated that the collaboration with Axion had been pleasant, but the slow clinical progress due to funding constraints led to the decision to reclaim the rights [1] - Shareholders had been advising the company to reclaim the overseas rights for the two products, making this an opportune moment for the company [1] Group 3: Product Information - IMM2510 is a PD-L1/VEGF bispecific antibody, which is a significant target in tumor immunotherapy, and its potential to disrupt the PD-1 market is highly anticipated [2] - The market for PD-1/VEGF bispecific antibodies has seen increased activity since 2024, with notable deals such as the $1.25 billion upfront payment received by a competitor for a similar product [2] Group 4: Future Plans - Yiming Anke expressed confidence in the therapeutic potential of IMM2510 and IMM27M and aims to accelerate their clinical development [3] - The company plans to seek new business development partnerships with large multinational pharmaceutical companies, which will be simplified by reclaiming the rights from Axion [3]
今年起单位代扣代缴增值税 个人偷税将变难
Di Yi Cai Jing· 2026-01-07 09:23
以前个人自行申报缴纳增值税,而今年起付钱的单位需要替个人代扣代缴增值税,此前一些个人偷税情 形或不复存在。 今年起增值税法和增值税实施条例正式施行。其中,增值税法实施条例明确,自然人发生符合规定的应 税交易,支付价款的境内单位为扣缴义务人。代扣代缴的具体操作办法,由国务院财政、税务主管部门 制定。 上海国家会计学院副教授葛玉御告诉第一财经,以前个人要去税务局代开发票来缴纳增值税,但实际上 因各种原因,部分个人并没有缴税,而支付价款单位也没有代扣代缴义务。但今年起随着上述增值税法 实施条例实施,自然人增值税征管有了创新,引入了"支付方代扣代缴义务",以后境内单位就需要给个 人代扣代缴增值税。这将与"劳务费反向申请代开发票"形成组合拳,意味着对自然人的税收征管在逐步 加强。 葛玉御举例,比如专家教授给高校、企业授课,高校、企业给他支付劳务报酬,这属于典型的增值税应 税服务,未来单位不仅要代扣代缴个人所得税,还得代扣代缴增值税。 所谓代扣代缴指税收法律、行政法规明确规定的扣缴义务人,在支付款项时代税务机关从纳税人收入中 扣留并解缴税款的征管方式。比如很多企事业单位职工熟悉的单位代扣代缴个人所得税。 "而今年起增值税 ...
两个月股价涨超三倍偏离基本面,连续跨界的国晟科技今起被停牌
Di Yi Cai Jing· 2026-01-07 09:13
受困于光伏产业的周期,由园林业务跨界光伏后的国晟科技长期处于亏损状态。 因股价涨幅过高脱离基本面,国晟科技(603778.SH)今天起停牌,拟停牌时间不超过三个交易日。 国晟科技原名"乾景园林",以园林工程施工与景观设计业务起家,是国内生态园林主板上市第一股。 2020年至2022年的三年间,因园林业务需求萎缩及跨界转型的资金压力,乾景园林累计亏损超4亿元。 2022年11月,该公司以1.54亿元现金向国晟能源收购7家子公司股权谋求跨界光伏,并于2023年11月正 式改名为"国晟科技",主营业务从园林工程转变为"园林+光伏"双主业。 但受困于光伏产业的周期,此后的几年,国晟科技长期处于亏损状态。2023年和2024年的净亏损分别为 6888.01万元和1.06亿元,2025年前三季度净亏损为1.51亿元。 除了股价严重脱离基本面,另引起交易所关注的是,经营连年亏损、债台高筑的国晟科技的一系列高杠 杆对外投资操作。在锂电产业即将迎来新一轮周期反转的当口,国晟科技的第二次跨界瞄向固态电池和 锂电池关键配套部件。 2025年10月14日,国晟科技披露《关于对外投资暨关联交易的公告》称,二级控股子公司安徽国晟新能 源 ...
更多高价药有望用商保报销了 患者为何还难以获益
Di Yi Cai Jing· 2026-01-07 09:12
Core Viewpoint - The first edition of the "Commercial Health Insurance Innovative Drug Directory" has been implemented, which includes 19 innovative drugs with significant clinical value that exceed the payment capacity of basic medical insurance, potentially benefiting participants of the Huiminbao insurance program [1][3]. Group 1: Innovative Drug Directory - The directory includes drugs for critical areas such as tumors, rare diseases, neurodegenerative diseases, and metabolic diseases, filling gaps in the basic medical insurance catalog [1]. - CAR-T therapy is highlighted as a significant treatment option for difficult-to-treat blood cancer patients, with potential survival rates increasing from six months to over five years, although its high cost limits accessibility [1][3]. Group 2: Implementation Challenges - The successful use of these innovative drugs in hospitals remains a challenge, with some hospitals still navigating the application process for these drugs [2][3]. - The "three exclusions" policy allows drugs in the commercial health insurance directory to be excluded from basic medical insurance self-payment rate indicators and centralized procurement monitoring, but does not resolve the challenges of hospital access for these high-value drugs [3][4]. Group 3: Insurance Product Design - Some Huiminbao products have begun to integrate the innovative drug directory, offering increased reimbursement rates for drugs used during hospitalization [4][5]. - The reimbursement for innovative drugs is contingent upon their successful admission into hospitals, and if not, patients may not receive coverage for these drugs [4][5]. Group 4: Regulatory Support - Local medical insurance bureaus are encouraging retail pharmacies to stock drugs from the commercial health insurance innovative drug directory, which may help address the hospital admission challenges [5][6]. - There is ongoing dialogue between innovative drug companies and commercial insurance providers to explore the inclusion of these drugs in special drug directories, potentially bypassing hospital admission requirements [5][6]. Group 5: Coverage Variability - Some Huiminbao products show significant differences in reimbursement rates for pre-existing conditions versus non-pre-existing conditions, with non-pre-existing conditions receiving a higher reimbursement rate [5][6]. - Recent notifications from multiple local medical insurance bureaus support the design of new products by commercial insurance institutions based on the innovative drug directory to better meet patient needs and reduce medical costs [6].
今年起单位代扣代缴增值税,个人偷税将变难
Di Yi Cai Jing· 2026-01-07 09:11
葛玉御举例,比如专家教授给高校、企业授课,高校、企业给他支付劳务报酬,这属于典型的增值税应 税服务,未来单位不仅要代扣代缴个人所得税,还得代扣代缴增值税。 跟个税一样,未来单位也将代扣代个人应缴纳的增值税 以前个人自行申报缴纳增值税,而今年起付钱的单位需要替个人代扣代缴增值税,此前一些个人偷税情 形或不复存在。 今年起增值税法和增值税实施条例正式施行。其中,增值税法实施条例明确,自然人发生符合规定的应 税交易,支付价款的境内单位为扣缴义务人。代扣代缴的具体操作办法,由国务院财政、税务主管部门 制定。 上海国家会计学院副教授葛玉御告诉第一财经,以前个人要去税务局代开发票来缴纳增值税,但实际上 因各种原因,部分个人并没有缴税,而支付价款单位也没有代扣代缴义务。但今年起随着上述增值税法 实施条例实施,自然人增值税征管有了创新,引入了"支付方代扣代缴义务",以后境内单位就需要给个 人代扣代缴增值税。这将与"劳务费反向申请代开发票"形成组合拳,意味着对自然人的税收征管在逐步 加强。 当然,为了支持个人发展,目前国家出台了系列增值税优惠政策。 比如根据相关法规,个体工商户和其他个人未达到增值税起征点的,免征增值税。其中, ...
今日这些个股异动 主力加仓通信、银行板块
Di Yi Cai Jing· 2026-01-07 09:08
【振幅大】 -今日A股共有13只个股振幅超过20%; -惠同新材,天力复合、倍益康等个股振幅居前; 【换手率高】 -今日A股共有46只个股换手率超过30%; -C新广益,雷科防务、C陕旅等个股换手率居前; 【主力资金】 -主力资金今日净流入通信、银行、煤炭等板块,净流出国防军工、计算机、汽车等板块; -航天发展、格林美、北方华创、通宇通讯、南大光电资金净流入规模居前,分别净流入19.33亿元、 12.66亿元、12.57亿元、11.72亿元、8.80亿元; -雷科防务、海格通信、三花智控、立讯精密、东方财富资金净流出规模居前,分别净流出21.09亿元、 19.74亿元、19.26亿元、18.08亿元、17.91亿元。 (本文来自第一财经) ...